1. Articles from iR DIRECT

    irdirect.net

  2. 1-3 of 3
    1. Avinger Announces Successful Treatment of 500th Patient with Next-Generation Pantheris Device

      Avinger Announces Successful Treatment of 500th Patient with Next-Generation Pantheris Device

      Avinger, Inc. ( Nasdaq: AVGR ), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that physicians in 59 sites globally have successfully treated more than 500 patients with the next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD). The next-generation Pantheris was launched on a limited basis in the U.S. following receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) in late May 2018 and features a number of improvements intended to augment the performance and reliability of the product. Importantly, clinical results have remained consistently positive ...

      Read Full Article
      Mentions: FDA Avinger
    2. Avinger Announces Successful Treatment of First Patients Globally with Pantheris SV, a New Image-Guided Atherectomy Device Designed to Treat Smaller Vessels

      Avinger Announces Successful Treatment of First Patients Globally with Pantheris SV, a New Image-Guided Atherectomy Device Designed to Treat Smaller Vessels

      Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced the successful treatment of the first nine patients with Pantheris SV (Small Vessel) at two separate hospitals in Germany. Dr. Arne Schwindt, a vascular surgeon at St. Franziskus Hospital Muenster and longtime innovator with Lumivascular technology, performed the first procedures globally. Additional cases were performed by Dr. Ulrich Sunderdiek, an interventional radiologist and cardiac surgeon at Marienhospital Osnabrueck. Pantheris SV was used to successfully treat a variety of lesion types ...

      Read Full Article
    3. Avinger Provides Third Quarter 2018 Shareholder Update

      Avinger Provides Third Quarter 2018 Shareholder Update

      Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today reported results for the third quarter ended September 30, 2018. Third Quarter and Recent Highlights ● Achieved revenue of $2.0 million for the third quarter of 2018 ● Announced in September that physicians at 35 sites globally have successfully treated over 200 patients with the next-generation Pantheris image-guided atherectomy system ● Submitted a new 510(k) application to the U.S Food & Drug Administration (FDA) in August for the Pantheris SV (Small Vessel ...

      Read Full Article
      Mentions: Avinger
    1-3 of 3
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks